📇 Rhumatologue · PARIS CEDEX 13 · (75) · Hospitalier

M THIERRY DELBOT

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
12 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS CEDEX 13 (75)HospitalierRPPS 10000480094

📊 Reconnaissance scientifique : 10/100📝 29 articles publiés🇫🇷 Publications académiques françaises (1)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

18F-Fluorocholine PET/CT and Parathyroid 4D Computed Tomography for Primary Hyperparathyroidism: The Challenge of Reoperative Patients

World journal of surgery · 2019

📚 55 citations🎯 RCR 4.96Top 8% NIH

Lire l'abstract Crossref ↓

AbstractBackgroundTo evaluate FCH‐PET/CT and parathyroid 4D‐CT so as to guide surgery in patients with primary hyperparathyroidism (pHPT) and prior neck surgery.MethodsMedical records of all patients referred for a FCH‐PET/CT in our institution were systematically reviewed. Only patients with pHPT, a history of neck surgery (for pHPT or another reason) and an indication of reoperation were included. All patients had parathyroid ultrasound (US) and Tc‐99m‐sestaMIBI scintigraphy, and furthermore, some patients had 4D‐CT. Gold standard was defined by pathological findings and/or US‐guided fine‐needle aspiration with PTH level measurement in the washing liquid.ResultsTwenty‐nine patients were included in this retrospective study. FCH‐PET/CT identified 34 abnormal foci including 19 ectopic localizations. 4D‐CT, performed in 20 patients, detected 11 abnormal glands at first reading and 6 more under FCH‐PET/CT guidance. US and Tc‐99m‐sestaMIBI found concordant foci in 8/29 patients. Gold standard was obtained for 32 abnormal FCH‐PET/CT foci in 27 patients. On a per‐lesion analysis, sensitivity, specificity, positive and negative predictive values were, respectively, 96%, 13%, 77% and 50% for FCH‐PET/CT, 75%, 40%, 80% and 33% for 4D‐CT. On a per‐patient analysis, sensitivity was 85% for FCH‐PET/CT and 63% for 4D‐CT. FCH‐PET/CT results made it possible to successfully remove an abnormal gland in 21 patients, including 12 with a negative or discordant US/Tc‐99m‐sestaMIBI scintigraphy result, with a global cure rate of 73%.ConclusionFCH‐PET/CT is a promising tool in the challenging population of reoperative patients with pHPT. Parathyroid 4D‐CT appears as a confirmatory imaging modality.

Selection of patients with solitary thyroid nodules for operation

The European journal of surgery = Acta chirurgica · 2002

📚 26 citations🎯 RCR 1.06🔓 Open Access📄 PDF gratuit ↗

(18)F-fluorocholine PET/CT in MEN1 Patients with Primary Hyperparathyroidism

World journal of surgery · 2020

📚 22 citations🎯 RCR 1.98

Lire l'abstract Crossref ↓

AbstractBackgroundPrimary hyperparathyroidism (HPT1) is the most frequent endocrinopathy in multiple endocrine neoplasia type 1 (MEN1). Its surgical management is challenging. We aimed to describe and compare the imaging findings of parathyroid ultrasound (US), sestaMIBI scintigraphy (sestaMIBI), and 18F‐fluorocholine (FCH) PET/CT in a series of MEN1 patients with HPT1.MethodsRetrospective analysis of a cohort of MEN1 patients with HPT1 assessed by parathyroid US, sestaMIBI scintigraphy and SPECT/CT, and FCH‐PET/CT for potential surgery between 2015 and 2019.ResultsTwenty‐two patients with a confirmed diagnosis of MEN1 who presented with HPT1 and were assessed by the 3 imaging modalities were included. After imaging workups, 11 patients were operated on for the first time, 4 underwent a redo surgery, and 7 did not undergo an operation. The overall patient‐based positivity rate of imaging was 91% (20 of 22) for parathyroid US and 96% (21 of 22) for both sestaMIBI and FCH‐PET/CT. The 3 imaging modalities demonstrated negative findings in 1/22 patient who did not undergo surgery. Overall, 3 pathologic glands were not detected by any imaging technique. SestaMIBI and FCH‐PET/CT both resulted in the same 3 false‐positive results in ectopic areas with a significant uptake on two thymic carcinoid tumors and one inflammatory lymph node. FCH‐PET/CT provided more surgically relevant data than sestaMIBI in 4/11 patients with initial surgery and in 1/4 patient who underwent redo surgery.ConclusionsCompared to sestaMIBI scintigraphy, FCH‐PET/CT provides additional information regarding the number of pathologic parathyroid glands and their localization in MEN1 patients with HPT1.

Cookies & analyse de trafic

M THIERRY DELBOT

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (12) — classées par pathologie

Transversal12

Partager cette fiche